Filter Publications
Product
Year
February 2026
Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents
| Nature Medicine
Extracorporeal liver cross-circulation (ELC) using genetically modified pig livers may address an unmet need for temporary liver support in patients with acute or acute-on-chronic liver failure. read more →
February 2026
When should I repeat the endoscopy in my patient with compensated cirrhosis, whom I just scoped and who had no or small varices?
| Translational Gastroenterology and Hepatology
Current endoscopic surveillance intervals for patients with compensated advanced chronic liver disease (cACLD) are based primarily on the presence or size of esophageal varices and rely largely on expert opinion rather than objective risk stratification. In an analysis of 195 patients with no or small varices over an average follow-up of 5.3 years, the Disease Severity Index (DSI) from the HepQuant DuO test significantly predicted adverse clinical outcomes, demonstrating a stepwise increase in risk across stratified categories, while variceal size was not a significant predictor. These findings support incorporating DSI into surveillance strategies to better individualize the timing of repeat endoscopy and optimize care in cACLD. read more →
HepQuant DuO, HepQuant SHUNT
January 2026
HMG-CoA Reductase Inhibitors (Statins) May Preserve Hepatic Function and Reduce Portal-Systemic Shunting in Compensated Advanced Chronic Liver Disease: Results from the SHUNT-V Study
| Clinical and Translational Gastroenterology | In Press
Background and Aims: Factors associated with decline of hepatic function and increase in portal-systemic shunting, which herald clinical outcome in persons with compensated cirrhosis, are poorly characterized. We used cholate challenge to evaluate the associations of liver disease etiology, concomitant diabetes, and maintenance drug therapy, with the degree of hepatic dysfunction and portal-systemic shunting.
Conclusions: Concomitant use of statins alone or in combination with metformin was independently associated with preserved hepatic function (DSI) and reduced portal-systemic shunting (SHUNT%). read more →
HepQuant DuO, HepQuant SHUNT
January 2026
Hepatic cholate clearance as assessed by HepQuant-SHUNT is predictive of clinical outcomes in individuals with Fontan circulation
| International Journal of Cardiology Congenital Heart Disease
Fontan-associated liver disease [FALD] is universal in individuals with Fontan circulation [FC]. The dual cholate clearance test is a noninvasive, flow-dependent measure of liver function. We aim to explore the association between cholate clearance and clinical outcomes in this population. read more →
HepQuant SHUNT
January 2026
HepQuant DuO® Test Enhances Clinical Decision Making in Compensated Advanced Chronic Liver Disease
| Journal of Clinical Medicine | January 2026
The HepQuant DuO® test is a noninvasive, blood-based test that assesses global liver health by quantifying liver function and physiology. The test generates a disease severity index (DSI) for assessment of risk for portal hypertension and large esophageal varices (LEV) to aid in the upper endoscopy (EGD) decision, provides a definition of disease severity to aid in clinical management, and enables serial testing to monitor changes in liver health over time, either improvement or worsening.
A DSI cutpoint 18.3 was defined in a U.S. multi-center trial in advanced chronic hepatitis C (HALT-C) and validated in a second U.S. multi-center trial where the majority of cases (52%) had MASLD/MASH (SHUNT-V). In addition, the latter validation study included all common etiologies of cACLD, and a high percentage of the study subjects were overweight, obese, elderly, and had diabetes. In several studies, DSI has shown favorable diagnostic performance compared to other noninvasive tests.
Using real-world data, the analysis evaluated the impact of DSI 18.3 in the EGD
decision and in modifying decision making in patients with cACLD. read more →
HepQuant DuO